Key result
VT ablation in NICM links to ~29% lower VT recurrence and reduced mortality versus ICM.
Why the study?
Long-term outcomes following catheter ablation for ventricular tachycardia in non-ischemic cardiomyopathy are sparsely described compared to ischemic cardiomyopathy.
Does catheter ablation improve long-term outcomes in non-ischemic cardiomyopathy compared to ischemic cardiomyopathy patients with sustained VT?
Population
212 consecutive patients ablated for sustained VT (135 ICMP, 77 NICMP)
Comparison
NICMP vs ICMP undergoing VT ablation
Design
Single-center registry-based observational cohort study
Follow-up
Median of 36 months
Authors
Loading...
May guide etiology-specific VT ablation selection; leaves open need for randomized confirmation of survival benefit.
Cohort (n=212)
No
Does catheter ablation improve long-term outcomes in non-ischemic cardiomyopathy compared to ischemic cardiomyopathy patients with sustained VT?
Absolute Event Rate: 38.9% vs 54.8%
p-value: p=0.026
Catheter ablation for sustained VT in non-ischemic cardiomyopathy is safe and effective, demonstrating higher procedural success and lower long-term VT recurrence and mortality compared to ischemic cardiomyopathy.
Khosravi et al. (2025) conducted a cohort in Ventricular tachycardia (n=212). Catheter ablation in non-ischemic cardiomyopathy vs. Catheter ablation in ischemic cardiomyopathy was evaluated on VT recurrence (p=0.026). VT ablation in non-ischemic cardiomyopathy patients yielded lower VT recurrence (38.9% vs 54.8%, P=0.026) and overall mortality (7% vs 22%, P=0.007) compared to ischemic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: